TRIO Bladder: A Phase Ib Study of Durvalumab (MEDI 4736) Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation, Based on Molecular Subtypes in Muscle-Invasive Bladder Cancer
Latest Information Update: 08 Jul 2020
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; BCG; Gemcitabine; Mitomycin
- Indications Bladder cancer; Carcinoma
- Focus Adverse reactions
- Acronyms TRIO Bladder
Most Recent Events
- 01 Jul 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 03 Mar 2020 Planned initiation date changed from 1 Jan 2020 to 1 Jun 2020.
- 27 Nov 2019 Planned End Date changed from 1 Oct 2025 to 1 Jan 2026.